Search Count: 17
 |
Inactive Mu-Opioid Receptor With Nb6M, Nabfab, And Isoquinuclidine Compound #33
Organism: Homo sapiens
Method: ELECTRON MICROSCOPY Release Date: 2025-02-12 Classification: MEMBRANE PROTEIN |
 |
Inactive Mu-Opioid Receptor With Nb6M, Nabfab, And Isoquinuclidine Compound #020_E1
Organism: Homo sapiens, Synthetic construct
Method: ELECTRON MICROSCOPY Release Date: 2025-02-12 Classification: MEMBRANE PROTEIN Ligands: A1BNM |
 |
Locally-Refined Inactive Mu-Opioid Receptor With Nb6M, Nabfab, And Isoquinuclidine Compound #020_E1
Organism: Homo sapiens
Method: ELECTRON MICROSCOPY Release Date: 2025-02-12 Classification: MEMBRANE PROTEIN Ligands: A1BNM |
 |
Inactive Kappa-Opioid Receptor With Nb6M, Nabfab, And Isoquinuclidine Compound #020_E1
Organism: Mus musculus, Synthetic construct
Method: ELECTRON MICROSCOPY Release Date: 2025-02-12 Classification: MEMBRANE PROTEIN Ligands: A1BNM |
 |
Locally-Refined Inactive Kappa-Opioid Receptor With Nb6M, Nabfab, And Isoquinuclidine Compound #020_E1
Organism: Mus musculus
Method: ELECTRON MICROSCOPY Release Date: 2025-02-12 Classification: MEMBRANE PROTEIN Ligands: A1BNM |
 |
Organism: Escherichia coli
Method: X-RAY DIFFRACTION Release Date: 2024-10-23 Classification: HYDROLASE Ligands: A1AU5 |
 |
Organism: Escherichia coli
Method: X-RAY DIFFRACTION Release Date: 2024-06-19 Classification: HYDROLASE Ligands: A1AUT |
 |
Organism: Escherichia coli
Method: X-RAY DIFFRACTION Release Date: 2024-06-19 Classification: HYDROLASE Ligands: A1AU0 |
 |
Organism: Escherichia coli
Method: X-RAY DIFFRACTION Release Date: 2024-06-19 Classification: HYDROLASE Ligands: A1AU1 |
 |
Virtual Screening For Novel Sars-Cov-2 Main Protease Non-Covalent And Covalent Inhibitors
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:1.95 Å Release Date: 2023-07-05 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: U0R |
 |
Virtual Screening For Novel Sars-Cov-2 Main Protease Non-Covalent And Covalent Inhibitors
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:2.17 Å Release Date: 2023-06-28 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: TKX |
 |
Virtual Screening For Novel Sars-Cov-2 Main Protease Non-Covalent And Covalent Inhibitors
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:2.09 Å Release Date: 2023-06-28 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: TNI |
 |
Virtual Screening For Novel Sars-Cov-2 Main Protease Non-Covalent And Covalent Inhibitors
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:1.90 Å Release Date: 2023-06-28 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: U1J |
 |
Virtual Screening For Novel Sars-Cov-2 Main Protease Non-Covalent And Covalent Inhibitors
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:1.98 Å Release Date: 2023-06-28 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: U1R |
 |
Virtual Screening For Novel Sars-Cov-2 Main Protease Non-Covalent And Covalent Inhibitors
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:2.45 Å Release Date: 2023-06-28 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: U26 |
 |
Virtual Screening For Novel Sars-Cov-2 Main Protease Non-Covalent And Covalent Inhibitors
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:2.12 Å Release Date: 2023-06-28 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: U2B |
 |
Virtual Screening For Novel Sars-Cov-2 Main Protease Non-Covalent And Covalent Inhibitors
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:2.59 Å Release Date: 2023-06-28 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: U2I |